A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial by the Clinical Psychopharmacology Unit (University College London, London, UK) reports on Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Summary The trial by the Clinical Psychopharmacology Unit focused on “cannabis use disorder” and treatments of 400mg and 800mg of CBD for relief.
“substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using an adaptive Bayesian design.” States the Clinical Psychopharmacology Unit
Methodology of CBD THC Study
The trial by the Clinical Psychopharmacology Unit used medical industry standards for the CBD study.
a phase 2a,
double-blind,
placebo-controlled,
randomised,
adaptive Bayesian dose-finding design to identify efficacious
or inefficacious doses at a-priori interim and final analysis stages.
Participants meeting cannabis use disorder criteria from DSM-5 were randomly assigned (1:1:1:1) in the first stage of the trial to 4-week treatment with three different doses of oral cannabidiol (200 mg, 400 mg, or 800 mg) OR matched placebo during a cessation attempt
Read more about this trial is at ClinicalTrials.gov ( NCT02044809) and the EU Clinical Trials Register (2013-000361-36).
Find medical cannabis doctors near you!
OMNI Medical Services offers medical cannabis doctors and clinics for medical marijuana patients. Find a doctor near you!
OMNI provides tested and recommended CBD a products made in the USA. Order CBD online.
Comments